Literature DB >> 20713858

Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease.

Usama Gergis1, Jon Arnason, Rhonda Yantiss, Tsiporah Shore, Usama Wissa, Eric Feldman, Thasia Woodworth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20713858     DOI： 10.1200/JCO.2010.29.1682

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

1.  Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.

Authors:  Brian C Betts; Erin T St Angelo; Michael Kennedy; James W Young
Journal:  Blood       Date:  2011-09-22       Impact factor: 22.113

2.  Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels.

Authors:  Chien-Chun Steven Pai; Hui-Hua Hsiao; Kai Sun; Mingyi Chen; Takeshi Hagino; Joseph Tellez; Christine Mall; Bruce R Blazar; Arta Monjazeb; Mehrdad Abedi; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-23       Impact factor: 5.742

3.  Tocilizumab for steroid refractory acute graft-versus-host disease.

Authors:  Julianna V F Roddy; Bradley M Haverkos; Ali McBride; Kathryn M Leininger; Samantha Jaglowski; Sam Penza; Rebecca Klisovic; William Blum; Sumithira Vasu; Craig C Hofmeister; Don M Benson; Leslie A Andritsos; Steven M Devine; Yvonne A Efebera
Journal:  Leuk Lymphoma       Date:  2015-07-03

4.  Tocilizumab promotes corneal allograft survival in rats by modulating Treg-Th17 balance.

Authors:  Xiao-Song Wu; Xiao-Li Lu; Jing Wu; Ming Ma; Jian Yu; Zhen-Yu Zhang
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

5.  Tocilizumab for the treatment of steroid refractory graft-versus-host disease.

Authors:  William R Drobyski; Marcelo Pasquini; Kathy Kovatovic; Jeanne Palmer; J Douglas Rizzo; Ayman Saad; Wael Saber; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-13       Impact factor: 5.742

Review 6.  Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance.

Authors:  Cheng Zhang; Xi Zhang; Xing-Hua Chen
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

7.  Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.

Authors:  L Grkovic; K Baird; S M Steinberg; K M Williams; D Pulanic; E W Cowen; S A Mitchell; F T Hakim; K J Martires; D N Avila; T N Taylor; R B Salit; S D Rowley; D Zhang; D H Fowler; M R Bishop; R E Gress; S Z Pavletic
Journal:  Leukemia       Date:  2011-10-18       Impact factor: 11.528

8.  Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Authors:  Atsushi Ogata; Toshio Tanaka
Journal:  Int J Rheumatol       Date:  2012-01-18

9.  Phenome-driven disease genetics prediction toward drug discovery.

Authors:  Yang Chen; Li Li; Guo-Qiang Zhang; Rong Xu
Journal:  Bioinformatics       Date:  2015-06-15       Impact factor: 6.937

Review 10.  Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.

Authors:  Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Int J Biol Sci       Date:  2012-10-24       Impact factor: 6.580
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.